Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma

Completed · Phase 2

Conditions studied: Multiple Myeloma

In brief

This study will assess the ability of Doxorubicin, Vincristine and Dexamethasone plus arsenic trioxide to achieve an overall response rate of greater than 60%.

Key facts

Study ID

NCT00201695

Run by

Ohio State University Comprehensive Cancer Center

People needed

12

Starts

2004-07-01

Expected to finish

2008-08-01

Last updated by the study team

2015-06-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have Multiple Myeloma
• No prior chemotherapy, thalidomide, or corticosteroids treatments for Multiple Myeloma
• ECOG performance status must be 0-2

You may not qualify if…

• Resting left ventricular cardiac ejection fraction ≥50% by echo or MUGA scan.
• QT interval ≥480 msec on baseline ECG.
• No history of cardiac disease.
• Pregnant or breast-feeding.
• No history of hypersensitivity reactions attributed to a conventional formulation of doxorubicin HCL or the components of Doxil.
• History of prior or concurrent malignancy or myelodysplasia.

Where it is running

• Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.